Non-factor replacement therapies in hemophilia

Rüdiger E. Scharf

doi:10.1055/s-0037-1619836

Hämostaseologie, Table of Contents

Hamostaseologie 2017; 37(04): 238
DOI: 10.1055/s-0037-1619836

Editorial

Schattauer GmbH

Non-factor replacement therapies in hemophilia

Hot Topic

Rüdiger E. Scharf Prof. Dr.

¹Division of Experimental and Clinical Hemostasis, Hemotherapy and Transfusion Medicine, and Hemophilia Comprehensive Care Center, Institute of Transplantation Diagnostics and Cell Therapy, Heinrich Heine University Medical Center, Düsseldorf, Germany

› Author Affiliations

References
1 Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med 2015; 373: 389-391.
2 Shima M, Hanabusa H, Taki M. et al. Factor VIIImimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044-2053.
3 Klamroth R. A new era of treatment for patients with haemophilia A?. Hämostaseologie 2017; 37: 216-218.
4 Scharf RE. Hot topic: Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. Hämostaseologie 2016; 36: 195-198.
5 Tiede A. Thrombotic risks of non-factor replacement therapies in hemophilia. Hämostaseologie 2017; 37: 307-310.
6 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-818.
7 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819-828.